Therapeutic Efficacy of Basic Fibroblast Growth Factor in Patients With Vocal Fold Atrophy.

Therapeutic Efficacy of Basic Fibroblast Growth Factor in Patients With Vocal Fold Atrophy.:

Related Articles

Therapeutic Efficacy of Basic Fibroblast Growth Factor in Patients With Vocal Fold Atrophy.

Laryngoscope. 2020 Feb 08;:

Authors: Okui A, Konomi U, Kanazawa T, Komazawa D, Nakamura K, Matsushima K, Watanabe Y

Abstract

OBJECTIVES/HYPOTHESIS: In recent years, basic fibroblast growth factor (bFGF) injection has been used in the treatment of aging-related vocal fold atrophy. This injection not only improves closure by increasing the mass of the vocal fold but also improves its viscoelasticity. However, it has been reported that fibroblasts targeted by bFGF treatment decrease in number with age. The purpose of this study was to examine the effects of local injection of bFGF on age-related vocal atrophy as well as the influence of age on phonological outcomes.

STUDY DESIGN: Retrospective chart review.

METHODS: Fifty-three patients with age-related vocal fold atrophy underwent single injections of bFGF in their vocal folds. Phonological outcomes were evaluated 3 and 6 months after injection by acoustic and aerodynamic measurements.

RESULTS: Voice Handicap Index (VHI), maximum phonation time (MPT), jitter, shimmer, and pitch range improved after injection, and the effects continued for 6 months. In those over 70 years of age, VHI and MPT showed improvement at 3 and 6 months after injection. In addition, the degree of improvement in VHI and MPT did not differ significantly between those older than 70 years and those younger than 70 years.

CONCLUSIONS: Regenerative treatments dependent on bFGF single injection was safe and effective for both early and late elderly patients suffering of vocal fold atrophy.

LEVEL OF EVIDENCE: 2c Laryngoscope, 2020.

PMID: 32034961 [PubMed - as supplied by publisher]